P
GILD icon

&Partners’s Gilead Sciences GILD Stock Holding History

&Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53.6M Buy
384,268
+31,484
+9% +$4.41M 0.26% 79
2025
Q4 		$43.3M Buy
352,784
+49,405
+16% +$6M 0.23% 89
2025
Q3 		$33.6M Buy
303,379
+29,789
+11% +$3.39M 0.22% 102
2025
Q2 		$30.3M Buy
273,590
+171,989
+169% +$18.3M 0.23% 97
2025
Q1 		$11.4M Buy
101,601
+3,272
+3% +$338K 0.12% 163
2024
Q4 		$8.99M Buy
98,329
+37,315
+61% +$3.36M 0.11% 188
2024
Q3 		$5.12M Buy
61,014
+35,279
+137% +$2.69M 0.1% 201
2024
Q2 		$1.76M Buy
25,735
+21,511
+509% +$1.44M 0.08% 232
2024
Q1 		$309K Buy
+4,224
New +$325K 0.04% 358
2020
Q2 		– Sell
-2,700
Closed -$202K – 143
2020
Q1 		$202K Buy
+2,700
New +$187K 0.31% 100

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

&Partners's GILD Position: Q1 2026 in Review

&Partners increased its Gilead Sciences (GILD) stake by 8.9% in Q1 2026, buying an estimated $4.41M and bringing the position to 384,268 shares worth $53.6M. The position accounts for 0.26% of the portfolio, ranked #79.

&Partners first reported a position in GILD in Q1 2020 and has held it in 10 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • &Partners held 384,268 shares of Gilead Sciences worth $53.6M as of Q1 2026.
  • &Partners bought 31,484 Gilead Sciences shares in Q1 2026, an estimated $4.41M.
  • Gilead Sciences made up 0.26% of &Partners's portfolio in Q1 2026, its #79 holding.
  • &Partners first reported a position in Gilead Sciences in Q1 2020 and has held it in 10 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.